Incidence and clinical characteristics of herpes zoster after lung transplantation.

Détails

ID Serval
serval:BIB_56353E479C9B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Incidence and clinical characteristics of herpes zoster after lung transplantation.
Périodique
Journal of Heart and Lung Transplantation
Auteur⸱e⸱s
Manuel O., Kumar D., Singer L.G., Cobos I., Humar A.
ISSN
1557-3117
Statut éditorial
Publié
Date de publication
2008
Peer-reviewed
Oui
Volume
27
Numéro
1
Pages
11-16
Langue
anglais
Résumé
BACKGROUND: Solid-organ transplant recipients are at high risk for the development of herpes zoster. Epidemiologic data in lung transplant recipients are lacking. We determined the incidence and clinical characteristics of herpes zoster, and the risk factors for developing herpes zoster, after lung transplantation. METHODS: We retrospectively reviewed all adult (>18 years old) lung transplants performed at our institution between January 2001 and December 2005. Clinical characteristics of herpes zoster and potential risk factors associated with herpes zoster were assessed. RESULTS: Two hundred thirty-nine lung transplant recipients were included in the analysis. Median time of follow-up was 722 days (range 18 to 1,943 days). Thirty-five episodes of herpes zoster occurred in 29 patients, with a calculated incidence of 55.1 cases per 1,000 person-years of follow-up. The cumulative probability of herpes zoster was 5.8% at 1 year, 18.1% at 3 years and 20.2% at 5 years post-transplant. Only 2 of the 35 (5.7%) patients had disseminated cutaneous infection and none had visceral involvement. Recurrence of herpes zoster was seen in 13.8% of patients. Post-herpetic neuralgia was detected in 20% of cases. Anti-viral prophylaxis, primarily for cytomegalovirus (CMV), was protective against herpes zoster. No significant epidemiologic risk factors associated with herpes zoster could be identified. CONCLUSIONS: Herpes zoster is a common complication after lung transplantation with a peak incidence at between 1 and 4 years post-transplant. Preventive strategies would be beneficial for this population.
Mots-clé
Adult, Antibodies, Viral, Antiviral Agents, Canada, Female, Follow-Up Studies, Graft Rejection, Herpes Zoster, Herpes Zoster Vaccine, Herpesvirus 3, Human, Humans, Immunosuppressive Agents, Incidence, Lung Transplantation, Male, Middle Aged, Postoperative Complications, Risk Factors
Pubmed
Web of science
Création de la notice
20/02/2009 12:20
Dernière modification de la notice
20/08/2019 15:10
Données d'usage